Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.

@article{Medyouf2014MyelodysplasticCI,
  title={Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.},
  author={Hind Medyouf and Maximilian Mossner and J. Jann and Florian Nolte and Simon Raffel and Carl Herrmann and A Bastiaan Lier and Christian Eisen and Verena Nowak and Bettina Zens and Katja Muedder and Corinna Klein and Julia Oblaender and Stephanie Fey and Jovita Vogler and Alice Fabarius and Eva Riedl and Henning Roehl and Alexander Kohlmann and Marita Staller and Claudia Haferlach and Nadine Zoe M{\"u}ller and Thilo John and Uwe- Platzbecker and Georgia Metzgeroth and Wolf-Karsten Hofmann and Andreas Trumpp and Daniel Nowak},
  journal={Cell stem cell},
  year={2014},
  volume={14 6},
  pages={824-37}
}
Myelodysplastic syndromes (MDSs) are a heterogeneous group of myeloid neoplasms with defects in hematopoietic stem and progenitor cells (HSPCs) and possibly the HSPC niche. Here, we show that patient-derived mesenchymal stromal cells (MDS MSCs) display a disturbed differentiation program and are essential for the propagation of MDS-initiating Lin(-)CD34(+)CD38(-) stem cells in orthotopic xenografts. Overproduction of niche factors such as CDH2 (N-Cadherin), IGFBP2, VEGFA, and LIF is associated… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 10 times over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by
Altmetric.com